Total Payments
$377.33
2024 Payments
$120.16
Companies
13
Transactions
18
Medicare Patients
917
Medicare Billing
$129,206
Payment Breakdown by Category
Food & Beverage$282.33 (74.8%)
Education$95.00 (25.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $282.33 | 17 | 74.8% |
| Education | $95.00 | 1 | 25.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $95.00 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $40.54 | 2 | $0 (2019) |
| Celgene Corporation | $37.23 | 2 | $0 (2019) |
| Exelixis Inc. | $35.36 | 2 | $0 (2018) |
| Amgen Inc. | $33.09 | 2 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $30.16 | 2 | $0 (2019) |
| Tempus AI, Inc | $25.16 | 1 | $0 (2024) |
| PFIZER INC. | $16.76 | 1 | $0 (2018) |
| Myriad Genetic Laboratories, Inc. | $15.98 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $13.21 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $120.16 | 2 | Incyte Corporation ($95.00) |
| 2019 | $83.31 | 4 | Janssen Biotech, Inc. ($40.54) |
| 2018 | $115.60 | 8 | Exelixis Inc. ($20.53) |
| 2017 | $58.26 | 4 | Amgen Inc. ($33.09) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $95.00 | General |
| 06/06/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $25.16 | General |
| 12/19/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Oncology | ||||||
| 10/16/2019 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: Hematology / Oncology | ||||||
| 02/15/2019 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: Oncology | ||||||
| 02/08/2019 | Janssen Biotech, Inc. | Erleada (Drug), ZYTIGA, DARZALEX | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Oncology | ||||||
| 09/25/2018 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Oncology | ||||||
| 09/19/2018 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $12.46 | General |
| 08/16/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2018 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $10.83 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2018 | Myriad Genetic Laboratories, Inc. | BRACANALYSIS CDX (Device) | Food and Beverage | Cash or cash equivalent | $15.98 | General |
| Category: GERMLINE DNA SEQUENCING HEREDITARY CANCER AND REARRANGEMENT ANALYSIS | ||||||
| 03/28/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $11.55 | General |
| Category: BioOncology | ||||||
| 01/30/2018 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Hematology / Oncology | ||||||
| 01/23/2018 | PFIZER INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Oncology | ||||||
| 04/21/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $10.34 | General |
| Category: Oncology | ||||||
| 03/17/2017 | Amgen Inc. | Neulasta (Biological), NEUPOGEN, Vectibix | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Oncology | ||||||
| 02/10/2017 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 394 | 665 | $188,074 | $62,401 |
| 2022 | 4 | 297 | 446 | $131,348 | $46,525 |
| 2021 | 4 | 115 | 128 | $30,207 | $10,415 |
| 2020 | 3 | 111 | 122 | $30,015 | $9,865 |
Total Patients
917
Total Services
1,361
Medicare Billing
$129,206
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 252 | 499 | $154,690 | $51,831 | 33.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 36 | 36 | $15,858 | $4,840 | 30.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 52 | 57 | $12,198 | $3,982 | 32.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 54 | 73 | $5,328 | $1,748 | 32.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 185 | 325 | $100,750 | $35,804 | 35.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 38 | 38 | $14,516 | $5,282 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 62 | 71 | $15,194 | $5,164 | 34.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 12 | 12 | $888.00 | $274.89 | 31.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 62 | $13,088 | $4,430 | 33.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 31 | 35 | $10,791 | $3,721 | 34.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $3,516 | $1,301 | 37.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 19 | $2,812 | $964.08 | 34.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 50 | 55 | $13,805 | $4,519 | 32.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 40 | 46 | $8,188 | $2,740 | 33.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $8,022 | $2,606 | 32.5% |
About Dr. Nabiel Alkhouri, M.D
Dr. Nabiel Alkhouri, M.D is a Hematology & Oncology healthcare provider based in Cambridge, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497728489.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nabiel Alkhouri, M.D has received a total of $377.33 in payments from pharmaceutical and medical device companies, with $120.16 received in 2024. These payments were reported across 18 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($282.33).
As a Medicare-enrolled provider, Alkhouri has provided services to 917 Medicare beneficiaries, totaling 1,361 services with total Medicare billing of $129,206. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cambridge, OH
- Active Since 02/09/2006
- Last Updated 04/07/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1497728489
Products in Payments
- Revlimid (Drug) $37.23
- Cabometyx (Drug) $35.36
- DARZALEX (Biological) $22.80
- CALQUENCE (Drug) $19.82
- Kyprolis (Biological) $19.60
- Erleada (Drug) $17.74
- XTANDI (Drug) $16.76
- BRACANALYSIS CDX (Device) $15.98
- Neulasta (Biological) $13.49
- KEYTRUDA (Biological) $13.21
- TECENTRIQ (Biological) $11.55
- KISQALI (Drug) $10.83
- TAGRISSO (Drug) $10.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cambridge
Robert Fram, M.d, M.D
Hematology & Oncology — Payments: $159,285
Hematology & Oncology $159,285
Jeffrey Jones, M.d, M.D
Hematology & Oncology — Payments: $20,956
Hematology & Oncology $20,956
Iris Sheng, M.d, M.D
Hematology & Oncology — Payments: $847.19
Hematology & Oncology $847.19
Debashish Misra, M.d, M.D
Hematology & Oncology — Payments: $456.08
Hematology & Oncology $456.08
Dr. Thomas Caughey, Md, MD
Hematology & Oncology — Payments: $420.08
Hematology & Oncology $420.08
Anna Berkenblit, M.d, M.D
Hematology & Oncology — Payments: $67.56
Hematology & Oncology $67.56